Verastem, Inc. (VSTM): Price and Financial Metrics
GET POWR RATINGS... FREE!
VSTM POWR Grades
- Sentiment is the dimension where VSTM ranks best; there it ranks ahead of 98.74% of US stocks.
- The strongest trend for VSTM is in Stability, which has been heading up over the past 159 days.
- VSTM's current lowest rank is in the Momentum metric (where it is better than 4.74% of US stocks).
VSTM Stock Summary
- With a price/sales ratio of 33.24, VERASTEM INC has a higher such ratio than 95.43% of stocks in our set.
- With a year-over-year growth in debt of 751.1%, VERASTEM INC's debt growth rate surpasses 97.64% of about US stocks.
- In terms of volatility of its share price, VSTM is more volatile than 93.72% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to VERASTEM INC, a group of peers worth examining would be ATNM, AGLE, PRTC, EXEL, and SGTX.
- Visit VSTM's SEC page to see the company's official filings. To visit the company's web site, go to www.verastem.com.
VSTM Valuation Summary
- In comparison to the median Healthcare stock, VSTM's EV/EBIT ratio is 109.16% lower, now standing at -0.6.
- Over the past 136 months, VSTM's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for VSTM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VSTM | 2023-03-17 | 35.3 | 1.9 | -1.2 | -0.6 |
| VSTM | 2023-03-16 | 34.9 | 1.9 | -1.2 | -0.6 |
| VSTM | 2023-03-15 | 33.2 | 1.8 | -1.2 | -0.5 |
| VSTM | 2023-03-14 | 33.2 | 1.8 | -1.2 | -0.5 |
| VSTM | 2023-03-13 | 30.1 | 1.5 | -1.3 | -0.6 |
| VSTM | 2023-03-10 | 26.1 | 1.3 | -1.1 | -0.4 |
VSTM Growth Metrics
- Its 2 year revenue growth rate is now at -82.52%.
- Its 2 year price growth rate is now at -37.7%.
- Its 3 year price growth rate is now at -39.68%.
The table below shows VSTM's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 3.141 | -56.99 | -73.485 |
| 2022-06-30 | 3.143 | -52.735 | -78.181 |
| 2022-03-31 | 3.643 | -53.465 | -73.131 |
| 2021-12-31 | 2.053 | -53.502 | -71.2 |
| 2021-09-30 | 2.014 | -65.272 | -74.583 |
| 2021-06-30 | 80.659 | -9.698 | -38.659 |
VSTM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VSTM has a Quality Grade of C, ranking ahead of 63.22% of graded US stocks.
- VSTM's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
- NERV, BLUE, and OTLC are the stocks whose asset turnover ratios are most correlated with VSTM.
The table below shows VSTM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.015 | 0.994 | -0.646 |
| 2021-06-30 | 0.510 | 0.602 | -0.382 |
| 2021-03-31 | 0.478 | 0.611 | -0.535 |
| 2020-12-31 | 0.455 | 0.619 | -0.911 |
| 2020-09-30 | 0.476 | 0.624 | -1.030 |
| 2020-06-30 | 0.118 | 0.856 | -1.060 |
VSTM Price Target
For more insight on analysts targets of VSTM, see our VSTM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $6.25 | Average Broker Recommendation | 1.38 (Strong Buy) |
VSTM Stock Price Chart Interactive Chart >
VSTM Price/Volume Stats
| Current price | $0.44 | 52-week high | $2.13 |
| Prev. close | $0.44 | 52-week low | $0.29 |
| Day low | $0.42 | Volume | 266,000 |
| Day high | $0.44 | Avg. volume | 788,519 |
| 50-day MA | $0.55 | Dividend yield | N/A |
| 200-day MA | $0.75 | Market Cap | 87.92M |
Verastem, Inc. (VSTM) Company Bio
Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts.
Latest VSTM News From Around the Web
Below are the latest news stories about VERASTEM INC that investors may wish to consider to help them evaluate VSTM as an investment opportunity.
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian CancerBOSTON, March 15, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of Let’s Talk About LGSOC, a new initiative that calls attention to low-grade serous ovarian cancer (LGSOC). Let’s Talk About LGSOC provides detailed information about LGSOC and its symptoms, its differences from the more common high-grade serous ovarian cancer (HGSOC), tips and resources, and ways to connect with others |
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company ProgressBOSTON, March 14, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted recent progress. |
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven CancersBOSTON, February 02, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound RAF/MEK clamp avutometinib in RAS pathway-driven cancers. |
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred StockBOSTON, January 24, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the "Preferred Stock") to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the plac |
VSTM Price Returns
| 1-mo | -11.79% |
| 3-mo | 28.65% |
| 6-mo | -52.30% |
| 1-year | -64.23% |
| 3-year | -79.82% |
| 5-year | -85.85% |
| YTD | 9.32% |
| 2022 | -80.37% |
| 2021 | -3.76% |
| 2020 | 58.96% |
| 2019 | -60.12% |
| 2018 | 9.45% |
Continue Researching VSTM
Here are a few links from around the web to help you further your research on Verastem Inc's stock as an investment opportunity:Verastem Inc (VSTM) Stock Price | Nasdaq
Verastem Inc (VSTM) Stock Quote, History and News - Yahoo Finance
Verastem Inc (VSTM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...